argenex (NASDAQ:ARGX) Price Target Raised to $1,350.00

argenex (NASDAQ:ARGX – Get Free Report) had its price objective upped by stock analysts at Piper Sandler from $1,215.00 to $1,350.00 in a report issued on Monday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Piper Sandler‘s price target would indicate a potential upside of 40.62% from the stock’s previous close.

Several other analysts have also commented on the stock. Jefferies Financial Group reiterated a “buy” rating on shares of argenex in a research report on Monday, September 14th. The Goldman Sachs Group restated a “buy” rating on shares of argenex in a research report on Friday, September 25th. Sanford C. Bernstein reaffirmed a “buy” rating on shares of argenex in a research note on Thursday, October 8th. Morgan Stanley reduced their target price on shares of argenex from $1,190.00 to $1,130.00 and set an “overweight” rating on the stock in a report on Friday. Finally, UBS Group raised argenex from a “neutral” rating to a “buy” rating and increased their price target for the stock from $960.00 to $1,400.00 in a research note on Wednesday, August 26th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,163.18.

Check Out Our Latest Stock Analysis on ARGX

argenex Price Performance

argenex stock opened at $960.04 on Monday. argenex has a 52 week low of $661.85 and a 52 week high of $1,072.75. The firm’s 50-day simple moving average is $923.87 and its 200 day simple moving average is $860.78. The firm has a market capitalization of $60.38 billion, a PE ratio of 33.50, a P/E/G ratio of 0.89 and a beta of 0.48.

argenex (NASDAQ:ARGX – Get Free Report) last posted its earnings results on Friday, October 23rd. The company reported $7.80 earnings per share for the quarter, beating the consensus estimate of $7.44 by $0.36. The firm had revenue of $1.75 billion during the quarter. argenex had a net margin of 31.66% and a return on equity of 47.70%. On average, research analysts expect that argenex will post 28.41 EPS for the current fiscal year.

Institutional Trading of argenex

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Squarepoint Ops LLC lifted its stake in shares of argenex by 314.8% in the 2nd quarter. Squarepoint Ops LLC now owns 58,400 shares of the company’s stock valued at $54,182,000 after purchasing an additional 44,321 shares in the last quarter. Tidal Investments LLC grew its holdings in shares of argenex by 97.8% during the 2nd quarter. Tidal Investments LLC now owns 2,362 shares of the company’s stock worth $2,191,000 after purchasing an additional 1,168 shares during the period. Peregrine Capital Management LLC purchased a new stake in shares of argenex during the 2nd quarter worth about $27,584,000. BG Investment Services LLC acquired a new stake in argenex during the 3rd quarter worth approximately $1,397,000. Finally, Optiver Holding B.V. increased its position in argenex by 907.0% during the 1st quarter. Optiver Holding B.V. now owns 10,110 shares of the company’s stock worth $7,383,000 after purchasing an additional 9,106 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

About argenex

(Get Free Report)

argenx SE is a global immunology company focused on developing medicines for autoimmune diseases. Founded in 2008 and headquartered in the Netherlands, the company uses antibody engineering and other research approaches to identify and develop treatments for conditions with significant unmet medical needs. Its lead medicine is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo. These products target the neonatal Fc receptor (FcRn) and are approved in the United States for certain patients with generalized myasthenia gravis; Vyvgart Hytrulo is also approved for chronic inflammatory demyelinating polyneuropathy. argenx continues to study efgartigimod in additional diseases and develop other potential therapies. argenx operates internationally, with commercial activities and research collaborations across multiple markets.

Featured Stories

Analyst Recommendations for argenex (NASDAQ:ARGX)

Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.